The preclinically reported efficacy of MYC+ XPO-1 expressing DLBCL [102] could not be confirmed in a post hoc analysis of the SADAL trial, and the outcome was independent of the COO [104]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.